公开(公告)号：US20180161381A1

公开(公告)日：2018-06-14

申请号：US15375663

申请日：2016-12-12

Applicant: Mead Johnson Nutrition Company

Inventor： Sarmauli Manurung ,  Gabriele Gross ,  Teartse Tim Lambers ,  Eric A.F. van Tol

IPC: A61K35/747 ,  A23L33/00 ,  A23L33/135

CPC classification number: A61K35/747 ,  A23L33/135 ,  A23L33/40 ,  A23Y2220/73

Abstract: The present disclosure is directed to methods for reducing the risk of developing or reducing the severity of a viral infection, bacterial infection, or viral and bacterial co-infection in a subject comprising administering to the subject a nutritional composition comprising an effective amount of a soluble mediator preparation derived from a late-exponential growth phase of a probiotic culture, such as Lactobacillus rhamnosus GG (LGG). The present disclosure, in certain embodiments, is directed to methods for reducing inflammation in a subject with a viral infection, bacterial infection, or viral and bacterial co-infections, comprising administering to the subject a nutritional composition comprising an effective amount of a soluble mediator preparation from a late-exponential growth phase of a probiotic culture, such as LGG.

公开(公告)号：US20170360855A1

公开(公告)日：2017-12-21

申请号：US15644888

申请日：2017-07-10

Applicant: Mead Johnson Nutrition Company

Inventor： Yan Zhong ,  Teartse Tim Lambers ,  Gabriele Gross ,  Sarmauli Manurung ,  Eric A.F. van Tol ,  Rosaline Waworuntu

IPC: A61K35/747 ,  A23L29/00 ,  A23L33/135

CPC classification number: A61K35/747 ,  A23L29/065 ,  A23L33/135 ,  A23L33/40 ,  A23V2002/00 ,  A23Y2220/73 ,  A61K38/40 ,  A61K2035/115 ,  A61K2300/00

Abstract: The present disclosure is directed to methods for i) promoting gut regeneration, ii) promoting gut maturation and/or adaptation, iii) supporting gut barrier resistance and/or iv) protecting gut barrier function in a pediatric subject comprising administering to the pediatric subject a composition comprising an effective amount of a soluble mediator preparation derived from a late-exponential growth phase of a probiotic batch-cultivation process, such as Lactobacillus rhamnosus GG (LGG). The present methods advantageously provide the gut-protection benefits of LGG soluble mediators without introducing live bacterial culture to individuals with impaired gut barrier function. In some embodiments, the pediatric subject has impaired gut barrier function and/or short bowel syndrome. The present disclosure in other embodiments, directed methods for reducing visceral pain in a pediatric subject comprising administering to the pediatric subject a composition comprising an effective amount of a soluble mediator preparation from a late-exponential growth phase of a probiotic batch-cultivation process, such as LGG.

公开(公告)号：US20170128500A1

公开(公告)日：2017-05-11

申请号：US14934559

申请日：2015-11-06

Applicant: Mead Johnson Nutrition Company

Inventor： Yan Zhong ,  Teartse Tim Lambers ,  Gabriele Gross ,  Sarmauli Manurung ,  Eric A.F. van Tol ,  Rosaline Waworuntu

IPC: A61K35/747

CPC classification number: A61K35/747 ,  A23L29/065 ,  A23L33/135 ,  A23L33/40 ,  A23V2002/00 ,  A23Y2220/73 ,  A61K38/40 ,  A61K2035/115 ,  A61K2300/00

Abstract: The present disclosure is directed to methods for i) promoting gut regeneration, ii) promoting gut maturation and/or adaptation, iii) supporting gut barrier resistance and/or iv) protecting gut barrier function in a pediatric subject comprising administering to the pediatric subject a composition comprising an effective amount of a soluble mediator preparation derived from a late-exponential growth phase of a probiotic batch-cultivation process, such as Lactobacillus rhamnosus GG (LGG). The present methods advantageously provide the gut-protection benefits of LGG soluble mediators without introducing live bacterial culture to individuals with impaired gut barrier function. In some embodiments, the pediatric subject has impaired gut barrier function and/or short bowel syndrome. The present disclosure in other embodiments, directed methods for reducing visceral pain in a pediatric subject comprising administering to the pediatric subject a composition comprising an effective amount of a soluble mediator preparation from a late-exponential growth phase of a probiotic batch-cultivation process, such as LGG.

公开(公告)号：US09730969B2

公开(公告)日：2017-08-15

申请号：US14934559

申请日：2015-11-06

Applicant: Mead Johnson Nutrition Company

Inventor： Yan Zhong ,  Teartse Tim Lambers ,  Gabriele Gross ,  Sarmauli Manurung ,  Eric A. F. van Tol ,  Rosaline Waworuntu

IPC: A61K35/747 ,  A23L1/29 ,  A23L1/30

CPC classification number: A61K35/747 ,  A23L29/065 ,  A23L33/135 ,  A23L33/40 ,  A23V2002/00 ,  A23Y2220/73 ,  A61K38/40 ,  A61K2035/115 ,  A61K2300/00

Abstract: The present disclosure is directed to methods for i) promoting gut regeneration, ii) promoting gut maturation and/or adaptation, iii) supporting gut barrier resistance and/or iv) protecting gut barrier function in a pediatric subject comprising administering to the pediatric subject a composition comprising an effective amount of a soluble mediator preparation derived from a late-exponential growth phase of a probiotic batch-cultivation process, such as Lactobacillus rhamnosus GG (LGG). The present methods advantageously provide the gut-protection benefits of LGG soluble mediators without introducing live bacterial culture to individuals with impaired gut barrier function. In some embodiments, the pediatric subject has impaired gut barrier function and/or short bowel syndrome. The present disclosure in other embodiments, directed methods for reducing visceral pain in a pediatric subject comprising administering to the pediatric subject a composition comprising an effective amount of a soluble mediator preparation from a late-exponential growth phase of a probiotic batch-cultivation process, such as LGG.

公开(公告)号：US20170020950A1

公开(公告)日：2017-01-26

申请号：US14806877

申请日：2015-07-23

Applicant: Mead Johnson Nutrition Company

Inventor： Teartse Tim Lambers ,  Eric A.F. van Tol ,  Sarmauli Manurung

IPC: A61K38/01 ,  A61K35/741 ,  A61K31/716 ,  A61K35/74

CPC classification number: A61K38/018 ,  A23L33/18 ,  A23L33/19 ,  A23L33/40 ,  A23V2002/00 ,  A61K31/202 ,  A61K31/702 ,  A61K31/716 ,  A61K35/74 ,  A61K35/741 ,  C07K14/4732 ,  C12N9/1205 ,  C12Y207/01 ,  A23V2200/30 ,  A23V2200/304 ,  A23V2200/32 ,  A23V2200/324 ,  A23V2250/00 ,  A23V2250/54246 ,  A23V2250/55 ,  A23V2300/00 ,  A23V2300/28 ,  A61K2300/00

Abstract: A method for modulating a kinase by administering to a subject a nutritional composition comprising extensively hydrolyzed casein, extensively hydrolyzed casein fractions, or combinations thereof. A modulated kinase may be a kinase that regulates inflammatory signaling, immune tolerance, metabolic signaling, cell cycle and growth factor signaling. The nutritional composition may dose-dependently inhibit a range of serine, threonine and tyrosine kinases.

Abstract translation: 通过向受试者施用包含广泛水解的酪蛋白，广泛水解的酪蛋白级分或其组合的营养组合物来调节激酶的方法。 调节的激酶可以是调节炎症信号，免疫耐受，代谢信号，细胞周期和生长因子信号传导的激酶。 营养组合物可以剂量依赖地抑制丝氨酸，苏氨酸和酪氨酸激酶的范围。